RTW INVESTMENTS, LP - Q4 2015 holdings

Add to watchlist

$303 Million is the total value of RTW INVESTMENTS, LP's 29 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 25.0% .

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
ALNY BuyAlnylam Pharmaceuticals Inc$53,976,000
+25.9%
573,361
+7.4%
17.83%
+33.8%
LJPC BuyLa Jolla Pharmaceutical Co$29,279,000
-2.5%
1,084,416
+0.4%
9.67%
+3.7%
OMER BuyOmeros Corp$28,618,000
+432.9%
1,819,341
+271.3%
9.45%
+466.7%
KITE BuyKite Pharma Inc$25,815,000
+23.5%
418,935
+11.6%
8.53%
+31.3%
DRNA BuyDicerna Pharmaceuticals Inc$23,890,000
+45.1%
2,012,662
+0.4%
7.89%
+54.3%
ATRA NewAtara Biotherapeutics Inc.$11,460,000–433,923
+100.0%
3.78%–
AGEN BuyAgenus Inc$10,054,000
+4.9%
2,214,453
+6.3%
3.32%
+11.5%
SSRG BuySymmetry Surgical Inc$8,093,000
+12.6%
879,623
+8.9%
2.67%
+19.7%
BMY BuyBristol-Myers Squibb Co$7,546,000
+24.4%
109,701
+7.1%
2.49%
+32.3%
CORI BuyCorium International Inc$6,040,000
+12.3%
743,865
+29.3%
2.00%
+19.4%
GBT BuyGlobal Blood Therapeutics Incord$5,663,000
+45.4%
175,156
+89.6%
1.87%
+54.4%
DYAX BuyDyax Corp$4,356,000
+97.8%
115,795
+0.4%
1.44%
+110.4%
RGNX BuyRegenxbio Inc$3,674,000
-18.4%
221,326
+8.2%
1.21%
-13.3%
LPCN BuyLipocine Inc$2,851,000
+13.4%
220,515
+3.8%
0.94%
+20.6%
AXDX NewAccelerate Diagnostics Inc$2,309,000–107,467
+100.0%
0.76%–
IVTY BuyInvuity Inc$1,789,000
-27.1%
202,808
+15.9%
0.59%
-22.4%
CYTR BuyCytRx Corp$1,247,000
+16.0%
470,576
+3.8%
0.41%
+23.4%
ADAP BuyAdaptimmune Therapeutics-adrsponds adr$85,000
+1.2%
7,055
+0.4%
0.03%
+7.7%
NVRO NewNVRO 05/20/2016 PUT 50put$37,000–142
+100.0%
0.01%–
BRKB NewBerkshire Hathaway Inccl b new$7,000–50
+100.0%
0.00%–
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2016-05-24
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ALNYLAM PHARMACEUTICALS INC36Q3 202319.7%
MASIMO CORP32Q3 20235.8%
LA JOLLA PHARMACEUTICAL CO31Q2 20229.7%
REGENXBIO INC30Q4 202210.8%
AGENUS INC29Q2 20229.0%
PTC THERAPEUTICS INC28Q3 202312.8%
DICERNA PHARMACEUTICALS INC28Q3 202110.8%
MIRATI THERAPEUTICS INC26Q3 20236.2%
ARGENX SE26Q3 20235.3%
VERICEL CORP24Q3 20233.9%

View RTW INVESTMENTS, LP's complete holdings history.

Latest significant ownerships (13-D/G)
RTW INVESTMENTS, LP Q4 2015 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
ROCKET PHARMACEUTICALS, INC.September 19, 202318,188,457-
ALLURION TECHNOLOGIES, INC.August 11, 20233,457,7077.4%
Orchestra BioMed Holdings, Inc.May 05, 20235,620,64515.7%
Renovacor, Inc.Sold outApril 05, 20230-
Adverum Biotechnologies, Inc.Sold outFebruary 14, 202300.0%
Aptevo Therapeutics Inc.Sold outFebruary 14, 202300.0%
ASLAN Pharmaceuticals LtdSold outFebruary 14, 202300.0%
Athira Pharma, Inc.Sold outFebruary 14, 202300.0%
BELLUS Health Inc.Sold outFebruary 14, 202300.0%
Clearside Biomedical, Inc.Sold outFebruary 14, 202300.0%

View RTW INVESTMENTS, LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
SC 13D/A2024-04-17
SC 13D/A2024-03-01
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View RTW INVESTMENTS, LP's complete filings history.

All filings

View complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (302757000.0 != 302756000.0)
  • The reported has been restated
  • The reported has been amended

Export RTW INVESTMENTS, LP's holdings

CSVXLS